Asahi Kasei pushes into human trials with new autoimmune drug candidate
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Subscribe To Our Newsletter & Stay Updated